Shots:

• The P-III KITE involves assessing of Beovu (brolucizumab- 6mg) vs aflibercept (2mg) in 360 patients with DME across 80 centers in 23 countries. In 2EPs- more than half of Beovu patients were maintained on a 3mos. dosing interval through year one- following the loading phase
• Results: met its 1EPs & 2EPs i.e. non-inferiority to aflibercept in mean change BCVA @52wks. & superior improvement in CST @40wks. respectively. The therapy was well-tolerated- and the rate of intraocular inflammation was equivalent between Beovu and aflibercept
• Novartis is evaluating Beovu across wet AMD- DME- retinal vein occlusion- and proliferative diabetic retinopathy and is currently conducting a second study in DME- KESTREL2- anticipating its results in late 2020

­ Ref: Novartis | Image: Novartis